Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined reagent and system for evaluating the prognosis of chronic lymphocytic leukemia

A technology for lymphocytes and leukemia, applied in the field of medical technology detection, can solve problems such as time-consuming and difficult to use, and achieve the effects of facilitating result judgment, improving result accuracy, and rapid detection

Active Publication Date: 2022-05-06
GUANGZHOU KINGMED DIAGNOSTICS CENT
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Based on this, it is necessary to provide a combined reagent and system for evaluating the prognosis of chronic lymphocytic leukemia in view of the cumbersome, time-consuming, and difficult-to-use problems in the existing detection methods. Using the combined reagent and system, flow cytometric Surgical evaluation of CLL prognosis has the advantages of simple and rapid operation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined reagent and system for evaluating the prognosis of chronic lymphocytic leukemia
  • Combined reagent and system for evaluating the prognosis of chronic lymphocytic leukemia
  • Combined reagent and system for evaluating the prognosis of chronic lymphocytic leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] A combined reagent for evaluating the prognosis of chronic lymphocytic leukemia, the monoclonal antibodies in each group are respectively labeled with the following fluorescent labels FITC, PE, ECD, PE-Cy TM 5. PE-CY7, as follows:

[0062] Antibody combination 1: CD5, IgG1, CD3, CD19, CD45;

[0063] Antibody combination 2: CD5, ZAP70, CD3, CD19, CD45;

[0064] Antibody combination 3: CD38, CD49d, CD19, CD5, CD45.

[0065] The fluorescent labels and dosages of relevant monoclonal antibodies in the above combinations are shown in the table below.

[0066] Table 2. The dosage of each monoclonal antibody

[0067] fluorescent label Tube 1 (Antibody Mix 1) Tube 2 (antibody mix 2) Tube 3 (antibody combination 3) FITC CD5-5μl CD5-5μl CD38-5μl PE IgG1(mouse)-5μl ZAP70-5μl CD49d-10 μl ECD CD3-5μl CD3-5μl CD19-10μl PE-Cy TM 5

[0068] Note: The concentration gradient of the commercially available antibodies was verified ...

Embodiment 2

[0070] A system for evaluating the prognosis of chronic lymphocytic leukemia, including: a detection module, a data acquisition module and a data analysis module.

[0071] The detection module performs flow cytometry detection on the cells to be tested;

[0072] The data acquisition module acquires the flow cytometry detection result data of the cells to be tested stained with the combined reagent described in Example 1;

[0073] The data analysis module analyzes the above acquired data, and evaluates the prognosis of chronic lymphocytic leukemia according to predetermined criteria.

[0074] The specific workflow of using the above system is as follows:

[0075] 1. Prepare reagents.

[0076] The combination reagents described in Example 1 were prepared.

[0077] 2. Prepare a single cell suspension.

[0078] The sample source of the cells to be tested can be bone marrow, peripheral blood, pleural effusion, ascites, etc., and the concentration is adjusted to 1×10 according t...

Embodiment 3

[0102] The system for evaluating the prognosis of chronic lymphocytic leukemia in Example 2 was used to evaluate the prognosis of chronic lymphocytic leukemia, and 166 daily samples were randomly selected for detection. The positive rate of IGHV gene mutation detection was 81.2%, and the coincidence rate between the results of this method and the results of IGHV reached 85.3% %, proving that the above system can comprehensively and rapidly evaluate the prognosis of chronic lymphocytic leukemia through multi-parameter flow cytometry analysis.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a combined reagent and system for evaluating the prognosis of chronic lymphocytic leukemia, belonging to the field of medical technology detection. The combination reagent includes at least one of the following antibody combinations: antibody combination 1, including CD5, IgG1, CD3, CD19 and CD45 antibodies; antibody combination 2, including CD5, ZAP70, CD3, CD19 and CD45 antibodies; antibody combination 3: Includes CD38, CD49d, CD19, CD5, and CD45 antibodies. Among the above-mentioned antibody combinations against CLL of the present invention, the expressions of ZAP70, CD38, and CD49d are of great value in evaluating prognosis, and ZAP70 is one of the more accurate ones, but its clinical application is limited due to intracellular staining and gating techniques, and this The invention solves this problem to the greatest extent. In addition, two indicators are added. Combining these markers can provide a more comprehensive assessment of the prognosis of chronic lymphocytic leukemia.

Description

technical field [0001] The invention relates to the field of medical technology detection, in particular to a combined reagent and system for evaluating the prognosis of chronic lymphocytic leukemia. Background technique [0002] Chronic lymphocytic leukemia (CLL) is a malignant tumor that originates in hematopoietic tissue. Tumor cells accumulate in the blood, bone marrow, and lymphoid tissues. More than 95% of CLL is the clonal proliferation of B cells (i.e. B-CLL), and less than 5% of the cases are T cell phenotype (i.e. T-CLL). See a doctor for lymph node enlargement or unexplained increase in the absolute value of lymphocytes. Patients have non-specific manifestations such as mild fatigue and easy fatigue. Once it enters the advanced stage, in addition to generalized lymph nodes and splenomegaly, symptoms of weight loss, repeated infections, bleeding and anemia may appear. Due to the older age of the susceptible population, patients often suffer from exacerbation of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/574
Inventor 潘建华张静文郑倩李明敏郭鸣琪
Owner GUANGZHOU KINGMED DIAGNOSTICS CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com